1. Accueil Zonebourse
  2. Actions
  3. France
  4. Euronext Paris
  5. Sanofi
  6. Actualités
  7. Autres langues
    SAN   FR0000120578

SANOFI

(SAN)
  Rapport
Temps réel Euronext Paris  -  27/05 17:37:47
102.38 EUR   -1.18%
17:11Les ADR européens sont en hausse vendredi
MT
15:17Inovio Pharmaceuticals affirme que la thérapie combinée contre le cancer du cerveau a produit une réponse immunitaire dans un essai de phase 1/2
MT
14:20SANOFI : Berenberg n'est pas inspiré par le dossier
ZD
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteurAnalyses Zonebourse
Actualités dans d'autres langues sur SANOFI
17:11European ADRs Move Higher in Friday Trading
15:17Inovio Pharmaceuticals Says Brain Cancer Combination Therapy Produced Immune Response i..
26/05Sanofi - European Week Against Cancer 2022 - Interview with Santiago Aguirre, Market Le..
26/05SANOFI : FDA approves Dupixent® (dupilumab) as first treatment for adults and children age..
25/05French health body backs new COVID vaccine booster campaign for this autumn
23/05Fitch Raises Sanofi's Outlook To Positive From Stable on Transition Plan, Profitability
23/05BOLSA DE MADRID : Un punto bajo que cae
23/05France's Sanofi Wins US FDA Nod for Eosinophilic Esophagitis Drug
20/05Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis
20/05PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first treatment for adults and child..
20/05PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first treatment for adults and child..
20/05Sanofi's Dupixent wins U.S. approval for bigger use
20/05FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment
20/05SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
20/05Sanofi's Xenpozyme Secures Positive Opinion From the European Medicines Agency's CHMP
20/05BOLSA DE MADRID : La mini tabla de salvación es china
18/05TRANSCRIPT : Sanofi - Special Call
17/05Sanofi Announces New Nirsevimab Data Analyses Reinforce Efficacy Against RSV
17/05ASCO - New data from fast-growing innovative Oncology pipeline and portfolio to be pres..
17/05MARKETSCREENER'S WORLD PRESS REVIEW : May 17, 2022
17/05Unilever, Uber, Zurich Call For 2035 Ban On Combustion Engines In Europe
16/05Sanofi - Sarclisa (isatuximab) combination provides unprecedented median progression fr..
16/05Sarclisa® (isatuximab) combination provides unprecedented median progression free surv..
16/05Sanofi Says Multiple Myeloma Combination Therapy Shows Longer Progression-Free Survival..
16/05BOLSA DE MADRID : Aterrizaje brusco en China
16/05Sanofi To Appeal French Court Ruling To Compensate Family For Epilepsy Drug Side Effect..
16/05Sanofi Says Phase 3 Study of Sarclisa Showed Longer Progression-Free Survival
16/05Sanofi's Blood Cancer Drug Prolongs Progression-free Survival By 36 Months In Late-stag..
15/05PRESS RELEASE : Sarclisa® (isatuximab) combination provides unprecedented median progressi..
15/05Sarclisa® Combination Provides Unprecedented Median Progression Free Survival in Patien..
15/05PRESS RELEASE : Sarclisa® (isatuximab) combination provides unprecedented median progressi..
11/05Sanofi Says Nirsevimab Showed Nearly 80% Efficacy Against Respiratory Syncytial Virus
11/05Sanofi-AstraZeneca's Respiratory Syncytial Virus Drug Shows 80% Efficacy in Pooled Data..
11/05PRESS RELEASE : New nirsevimab data analyses reinforce efficacy against RSV
11/05PRESS RELEASE : New nirsevimab data analyses reinforce efficacy against RSV
10/05European Stocks Rebound As Volatility Continues to Dominate Markets
10/05Rallybio Secures Global Rights to Sanofi's Antibody Candidate to Treat Anemia
10/05Acerus Pharmaceuticals Reports Q1 Total Revenue of US$0.8 Million; Company Update and O..
09/05IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi
06/05Igm Biosciences, Inc. Announces Closing of Global Collaboration Agreement with Sanofi
06/05EuroAPI gains on market debut after spin-off from Sanofi
06/05Sanofi Spinoff EUROAPI Gains 5% in Euronext Paris Debut
06/05BOLSA DE MADRID : Don't Look Up
04/05Regeneron's COVID drug sales outside U.S. help revenue beat
04/05Will The Supreme Court Take The Bait? CVSG Issued And Other Updates In The Amgen v. San..
04/05FOUNDATION S : Sanofi's new philanthropic spearhead
04/05PRESS RELEASE : Foundation S: Sanofi's new philanthropic spearhead
03/05Annual General Meeting of May 3, 2022
03/05PRESS RELEASE : Annual General Meeting of May 3, 2022
03/05PRESS RELEASE : Annual General Meeting of May 3, 2022
03/05Sanofi Appoints Approves Appointment of Carole Ferrand, Emile Voest and Antoine Yver as..
03/05Sanofi Approves Cash Dividend, Payable on May 10, 2022
03/05TRANSCRIPT : Sanofi - Shareholder/Analyst Call
02/05Denali Therapeutics, Sanofi Start Phase 2 Trial for ALS Inhibitor
02/05L'agenda di domani
02/05L'agenda della settimana
29/04SANOFI : teams up with McLaren Racing to accelerate industrial excellence - Form 6-K
29/04L'agenda della prossima settimana
29/04Sanofi Teams Up with Mclaren Racing to Accelerate Industrial Excellence
28/04SANOFI : Q1 2022 business EPS(1) up 16.1% at CER driven by higher sales and improving marg..
28/04Strong earnings spur rally across European stocks
28/04BioMarin Announces Record Revenues in First Quarter 2022
28/04TRANSCRIPT : Sanofi, Q1 2022 Earnings Call, Apr 28, 2022
28/04SANOFI : supera las expectativas del consenso y confirma los objetivos para 2022
28/04SANOFI : Q1 Earnings Snapshot
28/04Sanofi mit überraschend starkem Jahresauftakt
28/04Sanofi's Q1 Adjusted Earnings, Revenue Rise; Reaffirms 2022 Guidance
28/04Sanofi Confident In Full-Year Prospects As Dupixent, Consumer Healthcare Drive Strong F..
28/04BOLSA DE MADRID : La venganza de Meta
28/04Sanofi Earnings, Sales Rose in 1Q; Expects Further Growth in 2022
28/04Sanofi steigert Umsatz und Ergebnis
28/04INTERIM REPORT Q1/2022 : Our financial targets remain in place
28/04Sanofi ziet omzet stijgen
28/04Sanofi profit gain beats market view on bestseller drug Dupixent
28/04Sanofi's Q1 Profit Soars Over Dupixent's Sustained Performance, Higher Consumer Healthc..
1  2  3  4  5  6  7  8  9  10Suiv.